Resp Res
-
Randomized Controlled Trial
Randomised trial of once-daily vilanterol in children with asthma on inhaled corticosteroid therapy.
Inhaled corticosteroids (ICS) are effective maintenance treatments for childhood asthma; however, many children remain uncontrolled. Vilanterol (VI) is an inhaled long-acting beta-2 agonist which, in combination with the ICS fluticasone furoate, is being explored as a once-daily treatment for asthma in children. We evaluated the dose-response, efficacy, and safety of once-daily VI (6.25 μg, 12.5 μg and 25 μg) administered in the evening over 4 weeks, on background fluticasone propionate (FP) in children with asthma inadequately controlled on ICS. ⋯ VI plus FP did not result in significant improvements in lung function versus placebo plus FP, but was well tolerated at all doses assessed.